Ciffreo
About the trial
The Ciffreo trial is a randomized, double-blind, placebo-controlled phase III trial to evaluate the safety and efficacy of Pfizer's gene therapy construct PF-06939926 in boys with Duchenne muscular dystrophy. Approximately 99 boys aged between 4 and 8 years with Duchenne muscular dystrophy will be enrolled at 55 different study centers.
Laysummary: The Ciffreo trial will assess if an investigational gene therapy is safe and the effect it has on muscles in boys with Duchenne muscular dystrophy.
How DCR - CIU supports the trial
DCR - CIU is involved in multiple aspects of the trial conduct: the planning, coordination and conduct of the study visits; collection, processing, storage and shipping of biological samples, intravenous IMP administration and accountability, maintenance of the Investigator Site File, and data entry.
Principal Investigator
Prof. Dr. med. Andrea Klein, Kinderklinik, Universitätsspital Bern
Sponsor
Pfizer